隨著痛風(fēng)和高尿酸血癥發(fā)病率的逐年攀升，臨床常用治療藥物（別嘌醇、苯溴馬隆、非布司他等）市場銷售額也逐年遞增，但這些藥物均存在明顯的副作用，國內(nèi)外藥企已將研發(fā)重點(diǎn)放在更安全、更高效的新型降尿酸藥物尿酸鹽重吸收轉(zhuǎn)運(yùn)子1（URAT1）抑制劑領(lǐng)域，已上市的雷西那德在近幾年備受關(guān)注，而在研新藥SHR4640、SIM1909-13已處于臨床試驗(yàn)階段，同時用中醫(yī)藥治療高尿酸血癥和痛風(fēng)也是未來的研究方向。對治療痛風(fēng)及高尿酸血癥的藥物研究進(jìn)展進(jìn)行綜述，以期為臨床用藥和新藥研發(fā)提供參考。

As the incidence of gout and hyperuricemia climbed annually, the market sales of allopurinol, benzbromarone and febuxostat, which are common therapeutic drugs in clinic, also increased year by year, but these drugs all have obvious side effects, and the pharmaceutical companies at home and abroad have focused their research and development on safer and efficient new urate lowering URAT1, The marketed representative drug, Lesinurad, has received much attention in recent years, while the on study drugs SHR4640 as well as SIM1909-13 are now all in clinical trials. Concomitant use of traditional Chinese medicine (TCM) for hyperuricemia and gout has also gained increasing attention. A review of the recent advances for gout and hyperuricemia will be performed to provide references for further research and applications.

R977.7

中國醫(yī)學(xué)科學(xué)院醫(yī)學(xué)與健康科技創(chuàng)新工程項(xiàng)目（2019-I2M-5-020）；天津市“項(xiàng)目+團(tuán)隊(duì)”重點(diǎn)培養(yǎng)專項(xiàng)（XC202030）